The global biologics market is estimated to reach $250bn in 2023

Monday, December 24, 2018 Genetics & Stem Cells News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, Dec. 24, 2018 /PRNewswire/ -- Protein Therapeutics, Monoclonal Antibodies, Fusion Proteins, Regenerative Medicines, Insulin, Other Recombinant Hormones, Plasma & Recombinant Coagulating Factors, Interferons, Enzyme Replacement, Stem Cell Therapies, Tissue Engineered Products, Gene Therapies

Read the full report: https://www.reportlinker.com/p04194707 The global biologics market is estimated to reach $250bn in 2023. The market is expected to grow at a CAGR of 4.8% from 2018 to 2023. In 2017, the
monoclonal antibodies submarket held 36.3% share of the global biologics market.How this report will benefit youRead on to discover how you can exploit the future business opportunities emerging in this sector.In this brand new 303-page report you will receive 166 charts– all unavailable elsewhere.The 303-page report provides clear detailed insight into the global biologics market. Discover the key drivers and challenges affecting the market.By ordering and reading our brand-new report today you stay better informed and ready to act.Report Scope- Global Biologics Market outlook from 2018-2028Global Biologics Submarkets analysis and forecast from 2018-2028:- Protein therapeutics, with sub-forecasting for insulin, other recombinant hormones, plasma and recombinant coagulating factors, interferons, enzyme replacement and other agents- Monoclonal antibodies (mAbs)- Fusion proteins- Regenerative medicine, with sub-forecasting for stem cell treatment, tissue engineering and gene therapy- VaccinesAnalysis and forecast from 2018-2028 for selected leading biologics in the market:- Lantus- NovoLog/NovoRapid- Humalog- Avonex- Rebif- Humira- Remicade- Tysabri- Herceptin- Kadcyla- Perjeta- Enbrel- Eylea- OsteoCel Plus- Trinity Evolution and Trinity Elite- Apligraf- Dermagraft- IMLYGICThis report provides individual revenue forecasts from 2018-2028 for these national markets:- The US- Japan- Germany- France- UK- Italy- Spain- China- India- Russia- BrazilOur study discusses the selected leading companies that are the major players in the biologics market:- AbbVie- Amgen- AstraZeneca- Bayer- Eli Lilly- GlaxoSmithKline (GSK)- Johnson & Johnson- Merck & Co., Inc.- Novartis- Pfizer- Roche- Sanofi S.A.This report discusses factors that drive and restrain this market. As well as opportunities and trends in this market.This report discusses the SWOT and STEP Analysis of the biologics market.Read the full report: https://www.reportlinker.com/p04194707 About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Cision View original content:http://www.prnewswire.com/news-releases/the-global-biologics-market-is-estimated-to-reach-250bn-in-2023-300770613.html

SOURCE Reportlinker



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store